https://orcid.org/0000-0003-4551-8439
Figures & data
Table 1. The clinical, histopathologic, and prognostic features of the patients.
Table 2. Results from immunohistochemical analysis of EBP50 and Merlin expression.
Figure 1. EBP50 staining images in uterine smooth muscle tumour types of some patients. A. Leiomyoma showed no immunoreactivity with EBP50 (immunoperoxidase, 200×). B. Mitotically active leiomyoma showed weak immunoreactivity with EBP50 (immunoperoxidase, 200×). C. STUMP showed moderate immunoreactivity with EBP50 (immunoperoxidase, 200×). D. LMS showed strong immunoreactivity with EBP50 (immunoperoxidase, 200×). Scale bar = 500 µm.
Figure 2. Strong nuclear EBP50 expression seen in some cases of LMS. A, B. Diffuse, nuclear EBP50 expression in two LMS cases (immunoperoxidase, 100×). Scale bar = 500 µm.
Figure 3. Merlin staining images in uterine smooth muscle tumour types of some patients. A. Leiomyoma showed moderate immunoreactivity with Merlin (immunoperoxidase, 200×). B. Mitotically active leiomyoma showed moderate immunoreactivity with Merlin (immunoperoxidase, 200×). C. STUMP showed moderate immunoreactivity with Merlin (immunoperoxidase, 200×). D. LMS showed strong immunoreactivity with Merlin (immunoperoxidase, 200×). Scale bar = 500 µm.
Table 3. Pairwise comparison of uterine smooth muscle tumor groups in terms of EBP50 and Merlin expression.
Figure 4. The distribution of age across all groups of uterine smooth muscle tumors is presented based on the expression of EBP50 (A) and Merlin (B).
Figure 5. Kaplan-Meier Curves for LMS patients with EBP50 (A) and Merlin (B).
Data availability statement
The data that support the findings of this study are available from the corresponding author, [UA], upon reasonable request.